347 related articles for article (PubMed ID: 15359572)
1. In situ transport of vinblastine and selected P-glycoprotein substrates: implications for drug-drug interactions at the mouse blood-brain barrier.
Cisternino S; Rousselle C; Debray M; Scherrmann JM
Pharm Res; 2004 Aug; 21(8):1382-9. PubMed ID: 15359572
[TBL] [Abstract][Full Text] [Related]
2. In vivo saturation of the transport of vinblastine and colchicine by P-glycoprotein at the rat blood-brain barrier.
Cisternino S; Rousselle C; Debray M; Scherrmann JM
Pharm Res; 2003 Oct; 20(10):1607-11. PubMed ID: 14620515
[TBL] [Abstract][Full Text] [Related]
3. Screening of multidrug-resistance sensitive drugs by in situ brain perfusion in P-glycoprotein-deficient mice.
Cisternino S; Rousselle C; Dagenais C; Scherrmann JM
Pharm Res; 2001 Feb; 18(2):183-90. PubMed ID: 11405289
[TBL] [Abstract][Full Text] [Related]
4. Expression, up-regulation, and transport activity of the multidrug-resistance protein Abcg2 at the mouse blood-brain barrier.
Cisternino S; Mercier C; Bourasset F; Roux F; Scherrmann JM
Cancer Res; 2004 May; 64(9):3296-301. PubMed ID: 15126373
[TBL] [Abstract][Full Text] [Related]
5. Effect of mdr1a P-glycoprotein gene disruption, gender, and substrate concentration on brain uptake of selected compounds.
Dagenais C; Zong J; Ducharme J; Pollack GM
Pharm Res; 2001 Jul; 18(7):957-63. PubMed ID: 11496955
[TBL] [Abstract][Full Text] [Related]
6. P-glycoprotein is more efficient at limiting uptake than inducing efflux of colchicine and vinblastine in HL-60 cells.
Declèves X; Chappey O; Boval B; Niel E; Scherrmann JM
Pharm Res; 1998 May; 15(5):712-8. PubMed ID: 9619779
[TBL] [Abstract][Full Text] [Related]
7. Role of P-glycoprotein in the blood-brain transport of colchicine and vinblastine.
Drion N; Lemaire M; Lefauconnier JM; Scherrmann JM
J Neurochem; 1996 Oct; 67(4):1688-93. PubMed ID: 8858954
[TBL] [Abstract][Full Text] [Related]
8. Modulation of P-glycoprotein transport activity in the mouse blood-brain barrier by rifampin.
Zong J; Pollack GM
J Pharmacol Exp Ther; 2003 Aug; 306(2):556-62. PubMed ID: 12721332
[TBL] [Abstract][Full Text] [Related]
9. Efavirenz does not interact with the ABCB1 transporter at the blood-brain barrier.
Dirson G; Fernandez C; Hindlet P; Roux F; German-Fattal M; Gimenez F; Farinotti R
Pharm Res; 2006 Jul; 23(7):1525-32. PubMed ID: 16779703
[TBL] [Abstract][Full Text] [Related]
10. Contribution of P-glycoprotein to bunitrolol efflux across blood-brain barrier.
Matsuzaki J; Yamamoto C; Miyama T; Takanaga H; Matsuo H; Ishizuka H; Kawahara Y; Kuwano M; Naito M; Tsuruo T; Sawada Y
Biopharm Drug Dispos; 1999 Mar; 20(2):85-90. PubMed ID: 10206323
[TBL] [Abstract][Full Text] [Related]
11. Evidence for an active transport of morphine-6-beta-d-glucuronide but not P-glycoprotein-mediated at the blood-brain barrier.
Bourasset F; Cisternino S; Temsamani J; Scherrmann JM
J Neurochem; 2003 Sep; 86(6):1564-7. PubMed ID: 12950465
[TBL] [Abstract][Full Text] [Related]
12. Blood-brain barrier (BBB) pharmacoproteomics: reconstruction of in vivo brain distribution of 11 P-glycoprotein substrates based on the BBB transporter protein concentration, in vitro intrinsic transport activity, and unbound fraction in plasma and brain in mice.
Uchida Y; Ohtsuki S; Kamiie J; Terasaki T
J Pharmacol Exp Ther; 2011 Nov; 339(2):579-88. PubMed ID: 21828264
[TBL] [Abstract][Full Text] [Related]
13. Influence of breast cancer resistance protein (Abcg2) and p-glycoprotein (Abcb1a) on the transport of imatinib mesylate (Gleevec) across the mouse blood-brain barrier.
Bihorel S; Camenisch G; Lemaire M; Scherrmann JM
J Neurochem; 2007 Sep; 102(6):1749-1757. PubMed ID: 17696988
[TBL] [Abstract][Full Text] [Related]
14. Variable modulation of opioid brain uptake by P-glycoprotein in mice.
Dagenais C; Graff CL; Pollack GM
Biochem Pharmacol; 2004 Jan; 67(2):269-76. PubMed ID: 14698039
[TBL] [Abstract][Full Text] [Related]
15. P-glycoprotein-mediated transport of itraconazole across the blood-brain barrier.
Miyama T; Takanaga H; Matsuo H; Yamano K; Yamamoto K; Iga T; Naito M; Tsuruo T; Ishizuka H; Kawahara Y; Sawada Y
Antimicrob Agents Chemother; 1998 Jul; 42(7):1738-44. PubMed ID: 9661014
[TBL] [Abstract][Full Text] [Related]
16. Interaction of nonpeptidic delta agonists with P-glycoprotein by in situ mouse brain perfusion: liquid chromatography-mass spectrometry analysis and internal standard strategy.
Dagenais C; Ducharme J; Pollack GM
J Pharm Sci; 2002 Jan; 91(1):244-52. PubMed ID: 11782913
[TBL] [Abstract][Full Text] [Related]
17. Regional differences in capillary density, perfusion rate, and P-glycoprotein activity: a quantitative analysis of regional drug exposure in the brain.
Zhao R; Pollack GM
Biochem Pharmacol; 2009 Oct; 78(8):1052-9. PubMed ID: 19523457
[TBL] [Abstract][Full Text] [Related]
18. Inhibitory effects of a cyclosporin derivative, SDZ PSC 833, on transport of doxorubicin and vinblastine via human P-glycoprotein.
Kusunoki N; Takara K; Tanigawara Y; Yamauchi A; Ueda K; Komada F; Ku Y; Kuroda Y; Saitoh Y; Okumura K
Jpn J Cancer Res; 1998 Nov; 89(11):1220-8. PubMed ID: 9914792
[TBL] [Abstract][Full Text] [Related]
19. What kinds of substrates show P-glycoprotein-dependent intestinal absorption? Comparison of verapamil with vinblastine.
Ogihara T; Kamiya M; Ozawa M; Fujita T; Yamamoto A; Yamashita S; Ohnishi S; Isomura Y
Drug Metab Pharmacokinet; 2006 Jun; 21(3):238-44. PubMed ID: 16858128
[TBL] [Abstract][Full Text] [Related]
20. Involvement of P-glycoprotein in blood-brain barrier transport of pentazocine in rats using brain uptake index method.
Moriki Y; Suzuki T; Fukami T; Hanano M; Tomono K; Watanabe J
Biol Pharm Bull; 2004 Jun; 27(6):932-5. PubMed ID: 15187451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
